A CMOS-compatible biosensor chip against infectious diseases
These chips are the brains behind Roswell Technologies’ powerful new platform for DNA sequencing, to support precision medicine, molecular diagnostics, rapid infectious disease testing, and DNA data storage. The Roswell platform delivers the power of molecular electronic sensing, to support a full spectrum of DNA sequencing and biosensing applications. This includes the spectrum of tests necessary for the detection and containment of infectious diseases, such as COVID-19, including sequencing, nucleic acid detection, antigen detection and antibody detection. The platform was also designed with the scalability to provide the solution for rapid, low-cost whole genome sequencing in precision medicine, for treating cancer and other diseases, as well as for reading massive amounts of digital data stored in DNA, which is envisioned as the future of archiving data at the global scale.
Molecular electronic sensor chips integrate single molecules as electrical sensor elements on standard semiconductor chips, making electronic biosensor devices massively scalable. While electronic biosensors have seen gradual adoption in DNA sequencing and other areas of testing, Roswell Biotechnologies claims its molecular electronics sensors represent an entirely new class of sensors, specifically designed to be maximally compatible with modern CMOS chip technology. As such, it delivers a technological breakthrough that significantly increases performance and lowers costs for high speed biomedical tests, the company says, enabling DNA sequencing and other forms of biomarkers sensing to be deployed on simple portable or handheld devices.
“Although molecular electronics has long been hailed as a scientific breakthrough, its commercial viability required the technology to be put on a standard semiconductor chip,” said Roswell Chief Science Officer Dr. Barry Merriman. “One of the significant hurdles to commercializing molecular electronics is the need for costly customized solutions for large scale manufacturing. Imec has overcome those challenges by utilizing state-of-the-art semiconductor manufacturing technology coupled with its deep experience in biosensor technology to commercialize molecular electronics using standard tools. We are excited to be partnering with imec on this effort.”
Imec and Roswell have successfully completed key proof-of-concept work and are now focused on final process development. The initial products are expected to be commercially available in 2021.
“Our partnership with Roswell is a great example of how imec is leveraging its leadership in state-of-the-art semiconductor manufacturing technology to make next-generation life-science instrumentation possible. We are very excited to collaborate with Roswell on the integration of their molecular electronics sensor and developing the fastest route to achieving large scale commercial manufacturing of their sensor chips. It is especially motivating to use our skills to make a direct impact in important areas of medicine, such as genome sequencing and infectious disease monitoring, as well as to open up new sectors such as DNA storage of Exabyte scale DNA”, said Dr. Simone Severi, program director for life science technologies at imec.
Roswell Biotechnologies – www.roswellbiotech.com
Related articles:
ADI prioritizes healthcare customers, in fight against Covid-19
Multiplex photonic sensor detects contaminants in milk
Wireless biosensor platform targets health-monitoring wearables
Implanted biosensor can be wirelessly charged
Imec and Genalyte report disposable silicon photonics biosensor chips
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
